Antioxidant nanoemulsion loaded with latanoprost enables highly effective glaucoma treatment
Journal of Controlled Release · 2023
DOI: 10.1016/j.jconrel.2023.08.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2023. Verfasst von Xuemeng Guo und 12 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou, Zhejiang 310058, PR China. Hauptthemen laut MEDLINE: Glaucoma, Prostaglandins F, Synthetic. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 54 Literaturangaben.
Abstract (Originalsprache)
Glaucoma is the third leading cause of blindness worldwide and is primarily characterized by elevated intraocular pressure (IOP). Common risk factors such as age, myopia, ocular trauma, and hypertension all increase the risk of elevated IOP. Prolonged high IOP not only causes physiological discomfort like headaches, but also directly damages retinal cells and leads to retinal ischemia, oxidative imbalance, and accumulation of reactive oxygen species (ROS) in the retina. This oxidative stress causes the oxidation of proteins and unsaturated lipids, leading to peroxide formation and exacerbating retinal damage. While current clinical treatments primarily target reducing IOP through medication or surgery, there are currently no effective methods to mitigate the retinal cell damage associated with glaucoma. To address this gap, we developed a novel nanoemulsion to co-delivery latanoprost and α-tocopherol (referred to as LA@VNE later) that prolongs ocular retention and enhances retinal permeability through localized administration. By encapsulating latanoprost, an IOP-lowering drug, and α-tocopherol, a potent antioxidant, we effectively reduced ROS accumulation (>1.5-fold in vitro and 2.5-fold in vivo), retinal ganglion cell (RGC) apoptosis (>9 fold), and inflammatory cell infiltration (>1.6 fold). Our approach showed strong biocompatibility and significant potential for clinical translation, providing a promising platform for the treatment of glaucoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou, Zhejiang 310058, PR China.
- College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou, Zhejiang 310058, PR China. Electronic address: liqingpo@zju.edu.cn.
- College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou, Zhejiang 310058, PR China. Electronic address: luolihua@zju.edu.cn.
- College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou, Zhejiang 310058, PR China; Zhejiang-California International Nanosystems Institute, Zhejiang University, Hangzhou 310058, PR China;…
Zitieren
APA
Guo, X., Zhang, J., Liu, X., Lu, Y., Shi, Y., Li, X., Wang, S., Huang, J., Liu, H., Zhou, H., Li, Q., Luo, L., & You, J. (2023). Antioxidant nanoemulsion loaded with latanoprost enables highly effective glaucoma treatment. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2023.08.004
Vancouver
Guo X, Zhang J, Liu X, Lu Y, Shi Y, Li X, et al. Antioxidant nanoemulsion loaded with latanoprost enables highly effective glaucoma treatment. Journal of Controlled Release. 2023. doi:10.1016/j.jconrel.2023.08.004
BibTeX
@article{Guo2023,
author = {Guo, Xuemeng and Zhang, Junlei and Liu, Xu and Lu, Yichao and Shi, Yingying and Li, Xiang and Wang, Sije and Huang, Jiaxin and Liu, Huihui and Zhou, Huanli and Li, Qingpo and Luo, Lihua and You, Jian},
title = {Antioxidant nanoemulsion loaded with latanoprost enables highly effective glaucoma treatment},
journal = {Journal of Controlled Release},
year = {2023},
doi = {10.1016/j.jconrel.2023.08.004}
}
EUVIMED